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ABSTRACT Uropathogenic Escherichia coli (UPEC) is the most common cause of urinary
tract infection, which in some patients can develop into life-threatening urosepsis. Se-
rum resistance is a key virulence trait of strains that cause urosepsis. Recently, we identi-
ﬁed a novel method of serum resistance in patients with Pseudomonas aeruginosa lung
infections, where patients possessed antibodies that inhibited complement-mediated
killing (instead of protecting against infection). These inhibitory antibodies were of the
IgG2 subtype, speciﬁc to the O-antigen component of lipopolysaccharide (LPS) and
coated the bacterial surface, preventing bacterial lysis by complement. As this mecha-
nism could apply to any Gram-negative bacterial infection, we hypothesized that inhibi-
tory antibodies may represent an uncharacterized mechanism of serum resistance in
UPEC. To test this, 45 urosepsis patients with paired blood culture UPEC isolates were
screened for serum titers of IgG2 speciﬁc for their cognate strain’s LPS. Eleven patients
had sufﬁciently high titers of the antibody to inhibit serum-mediated killing of UPEC iso-
lates by pooled healthy control sera. Depletion of IgG or removal of O-antigen restored
sensitivity of the isolates to the cognate patient serum. Importantly, the isolates from
these 11 patients were more sensitive to killing by serum than isolates from patients
with no inhibitory antibodies. This suggests the presence of inhibitory antibodies may
have allowed these strains to infect the bloodstream. The high prevalence of patients
with inhibitory antibodies (24%) suggests that this phenomenon is an important mecha-
nism of UPEC serum resistance. LPS-speciﬁc inhibitory antibodies have now been identi-
ﬁed against three Gram-negative pathogens that cause disparate diseases.
IMPORTANCE Despite improvements in the early detection and management of
sepsis, morbidity and mortality are still high. Infections of the urinary tract are one
of the most frequent sources of sepsis with Escherichia coli the main causative
agent. Serum resistance is vital for bacteria to infect the bloodstream. Here we re-
port a novel method of serum resistance found in patients with UPEC-mediated sep-
sis. Antibodies in sera usually protect against infection, but here we found that 24%
of patients expressed “inhibitory antibodies” capable of preventing serum-mediated
killing of their infecting isolate. Our data suggest that these antibodies would allow
otherwise serum-sensitive UPEC strains to cause sepsis. The high prevalence of pa-
tients with inhibitory antibodies in this cohort suggests that this is a widespread
mechanism of resistance to complement-mediated killing in urosepsis patients, in-
voking the potential for the application of new methods to prevent and treat sepsis.
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Urinary tract infections (UTIs) are one of the most common human infections. Theycan affect the bladder (cystitis), kidneys (pyelonephritis), and can lead to blood-
stream infection (urosepsis). UTIs account for roughly 9% of severe sepsis cases (1), with
uropathogenic Escherichia coli (UPEC) as the most common cause (2). UPEC isolated
from patients with pyelonephritis exhibit much higher serum resistance (82 to 93%)
than fecal E. coli isolates (57%) (3), and mechanisms that allow these strains to resist the
bactericidal activity of human serum are key virulence traits for the development of
urosepsis (4, 5).
Recently, we described a novel mechanism of serum resistance for Pseudomonas
aeruginosa where speciﬁc antibody, instead of targeting the bacteria for destruction,
protected the bacteria from complement-mediated lysis (6). These “inhibitory antibod-
ies” were present in patient serum at high titers, were of the IgG2 subtype, and
speciﬁcally recognized the O-antigen component of lipopolysaccharide (LPS). Our
results suggested that “inhibitory antibodies” prevented complement-mediated lysis by
binding at high density to the O-antigen, a target distal from the cell surface, and
sterically blocking access of complement to the cell membrane. Patients with inhibitory
antibodies had worse lung function than patients with normal serum killing, and
removal of these antibodies by plasmapheresis ameliorated infection-related sympto-
mology (7).
In addition to the observations above, we described similar inhibitory antibodies in
a subset of HIV-positive patients that had high titers of IgG speciﬁc for the LPS of
Salmonella enterica serovar Typhimurium (8). On the basis of these observations, we
hypothesized that this serum resistance mechanism could apply to any Gram-negative
bacterial infection where speciﬁc antibody to O-antigen is likely to be induced. Indeed,
a 56°C heat-stable serum factor in patients with UTIs that prevents bactericidal killing
by complement has already been reported (9, 10). Therefore, we sought to determine
whether inhibitory antibodies exist in patients presenting with urosepsis. Here, we
analyzed a panel of patients with UPEC-mediated urosepsis and identiﬁed the presence
of inhibitory antibodies in approximately one-quarter of these individuals. On the basis
of these observations, we suggest that inhibitory antibodies represent a widespread
mechanism for bacterial survival in the bloodstream.
We wished to determine whether patients with UPEC-mediated urosepsis had
O-antigen-speciﬁc inhibitory antibodies that might contribute to bacterial survival in
the bloodstream. Therefore, we obtained serum samples from 45 patients with uro-
sepsis (aged 33 to 98 years; 61% female), and the corresponding UPEC isolate recovered
from the bloodstream of each patient. To test whether these strains produced
O-antigen, we prepared LPS from all isolates and analyzed the preparations by silver
staining (11). This revealed that 38 strains possessed detectable long-chain O-antigen
(see Fig. S1 in the supplemental material).
LPS-speciﬁc IgG2 is associated with inhibition of complement-dependent bacterial
killing. However, the ability of IgG2 antibodies to inhibit killing is titer-dependent (7).
Therefore, for each patient we measured the titer of IgG2 in the serum that was speciﬁc
to the LPS isolated from their cognate infecting strain. Twenty-six of the 45 patient sera
had an LPS-speciﬁc IgG2 titer higher than pooled healthy control sera (HCS) (Fig. 1A).
Eleven sera had LPS-speciﬁc IgG2 titer of 180, potentially high enough to inhibit
serum killing (7).
The presence of inhibitory antibodies can be conﬁrmed by mixing patient serum
with HCS and demonstrating in a serum bactericidal assay (SBA) that this mixture is
poorer at bacterial killing than the HCS alone (6). Sera from 22 patients were tested in
this manner: 17 with IgG2 titers of 100 and 5 with titers of 30 (Fig. 1A). Fourteen of
the 22 matched isolates were resistant to HCS killing, so these sera were tested on
HCS-sensitive strains with either the same or cross-reacting O-antigen serotype. Eleven
sera with a titer of400 could inhibit the bactericidal activity of HCS, either against the
patient’s cognate isolate (Fig. 1B to G) or an appropriate serum-sensitive E. coli strain
(Fig. 1H). In contrast, sera with a titer of 190 could not inhibit serum-mediated killing
(Fig. S2). Thus, 11 of 45 urosepsis patients had serum that could signiﬁcantly block the
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bactericidal activity of HCS (Fig. S2A), correlating with titers of O-antigen-speciﬁc
antibody of 400. No serotype- or sequence type-speciﬁc associations were noted;
however, sequence type 73 was overrepresented in patients with inhibitory antibodies
(P  0.05) (Table S1). All strains belonged to E. coli phylogroup B2 or D.
Many of the E. coli isolates produced capsule, including some from patients with
inhibitory antibodies (PA26B, PA45B, and PA63B). To determine whether capsule had
any role in the antibody-mediated protection from serum killing, we performed an SBA
on strain PA45B and its isogenic capsule mutant PA45BkpsD (Fig. 2A). In contrast to the
wild type, the capsule mutant strain PA45BkpsD was killed in diluted HCS. However,
when the autologous patient serum was mixed 50:50 with HCS, killing of PA45BkpsD
was completely inhibited (Fig. 2A). Thus, capsule is not required for the protection
mediated by PA45 serum (45S). To conﬁrm that antibodies were responsible for the
inhibition of HCS killing, we puriﬁed IgG from 45S. The addition of puriﬁed 45S IgG
alone inhibited the killing of PA45BkpsD strain by HCS (Fig. 2B). In contrast, 45S
depleted of antibody did not inhibit HCS killing (Fig. S3). To conﬁrm that O-antigen was
FIG 1 (A) Titers of IgG2 in patient sera speciﬁc for the LPS of their cognate UPEC strain relative to pooled healthy control sera (HCS). Sera that either inhibited
(red circles) or did not inhibit (green circles) the bactericidal activity of pooled HCS when mixed 50:50 are indicated. Sera not tested for inhibition are indicated
by white circles. (B to H) HCS mixed 50:50 with PBS (HCS/PBS) can kill UPEC strains PA17B (B), PA25B (C), PA26B (D), PA48B (E), PA52B (F), PA70B (G), and PA26B
(H). Mixing this HCS 50:50 with patient serum 17S (HCS/17S) (B), 25S (C), 26S (D), 48S (E), 52S (F), 70S (G) and with 7S, 45S, 57S, 60S, and 63S (H) inhibits bacterial
killing.
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required for the antibody-mediated inhibition, we created a capsule, O-antigen double
mutant, PA45BkpsD waaL::cm. In contrast to the O-antigen-positive strain, addition of
either 45S or puriﬁed IgG from 45S was unable to inhibit HCS killing (Fig. 2B). Thus, IgG
speciﬁc for the O-antigen is responsible for inhibition of serum killing.
The assays above determined that some of the UPEC isolates tested (8/22) were
sensitive to HCS killing, even though they were isolated from blood. We therefore
examined all 45 isolates for sensitivity to killing by HCS. In these experiments, the 11
strains isolated from patients with inhibitory antibody were signiﬁcantly more sensitive
to killing by HCS over a 3-h incubation period than strains from patients that did not
have high-titer inhibitory antibody (P  0.001) (Fig. 2C). Thus, we conclude that the
presence of inhibitory antibody is frequently associated with serum-sensitive UPEC
bloodstream isolates.
The ability to resist the bactericidal effect of serum is a key virulence trait for the
survival of UPEC in the bloodstream (3–5, 12). The O-antigen represents a major
mechanism of UPEC serum resistance (13), but other factors, including capsule, also
contribute to this phenotype (12–14). Thus, the production of O-antigen is not uniquely
associated with protection from complement-mediated killing. Here we found that 24%
of urosepsis patients had inhibitory antibodies, indicating that this may represent an
important mechanism by which some UPEC strains exhibit resistance to complement-
mediated killing. Indeed, the majority of strains isolated from patients with inhibitory
FIG 2 (A) HCS mixed 50:50 with PBS or 45S serum could not kill wild-type PA45B. In contrast, HCS mixed
50:50 with PBS led to killing of the PA45BkpsD capsule mutant. Addition of 45S to HCS inhibited the
killing of PA45BkpsD strain. (B) Puriﬁed IgG from 45S when added to HCS 50:50 leads to complete
inhibition of HCS-PBS killing. In contrast, both HCS/PBS and HCS/puriﬁed IgG mixes lead to complete
killing of the O-antigen, capsule double mutant PA45BkpsD waaL::cm. (C) The bactericidal killing of all 45
UPEC isolates in undiluted HCS after either a 45-, 90-, or 180-min incubation. Strains isolated from
patients possessing inhibitory antibodies in their serum (red circles) were signiﬁcantly more sensitive to
HCS than UPEC strains isolated from patients without inhibitory antibodies (white circles). iAb, inhibitory
antibody. ***, P  0.001.
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antibodies (8/11) were sensitive to HCS, suggesting that these strains require the
presence of inhibitory antibodies to survive in the bloodstream. One strain (PA45B) was
serum-sensitive in HCS only after deletion of capsule; however, the presence of
inhibitory antibodies in the patient serum afforded full protection against complement-
mediated killing even in the mutant strain. Thus, these antibodies can protect bacteria
from serum killing regardless of capsule production.
A blocking factor of complement-mediated killing in patients with UTIs has previ-
ously been reported. In this 1966 study, nine patients with chronic pyelonephritis
possessed serum that blocked the ability of HCS to kill their cognate strain in a
strain-speciﬁc manner (9). Similarly, in a study from 1972, 9 of 48 patients with UTIs
possessed serum that could not kill their HCS-susceptible cognate strain; however, the
serum could kill a known susceptible E. coli (10). Strains isolated from patients with this
defect included E. coli, Proteus morganii, Proteus mirabilis, and Klebsiella spp. (10). The
serum defect was studied in detail for the two Proteus species and found to be IgG
speciﬁc for the LPS of each of the strains (15). In light of our new ﬁndings, we believe
it is likely that the patients in these studies also possessed inhibitory IgG2 speciﬁc for
the O-antigen of LPS. If this is correct, it strengthens the hypothesis that inhibitory
antibodies are common in patients that suffer UTIs, and these antibodies may exist for
multiple Gram-negative species. Indeed, having previously identiﬁed similar antibodies
against P. aeruginosa and S. Typhimurium, this study demonstrates that inhibitory
antibodies exist for an even wider range of Gram-negative bacteria.
In the studies described above, the serum-blocking factor disappeared following
successful treatment and eradication of the infecting organism (9, 10). Therefore, the
presence of the infecting organism seems necessary to maintain high titers of inhibitory
antibody, and eradication of the bacteria by antibiotic treatment may lead to subse-
quent loss of deleterious antibody. Additionally, we had recent success in treating
bronchiectasis patients who have inhibitory antibodies with plasmapheresis, where all
antibodies were removed from the serum and replaced with donor intravenous immu-
noglobulin, leading to improvement in health and the loss of culturable P. aeruginosa
in the sputum (7). This suggests that removing the inhibitory antibody in patients with
urosepsis, via plasmapheresis or other methods, may be an option to combat infections
caused by multidrug-resistant pathogens that do not respond to antibiotic treatment.
Methods. The paired plasma and UPEC blood culture isolates collected from the 45
urosepsis patients have been described previously (2). In silico serotyping was per-
formed using the online tool SerotypeFinder 1.1 (16). The capsule mutant strain
PA45BkpsD was described in a previous study (14). The capsule, O-antigen double
mutant strain PA45BkpsD waaL::cm was constructed as previously described (14).
Strains were grown in solid or liquid lysogeny broth (LB) at 37°C. This study was
performed in accordance with the ethical standards of The University of Queensland,
Princess Alexandra Hospital, and the Helsinki Declaration. The study was approved, and
the need for informed consent was waived by the institutional review board of the
Princess Alexandra Hospital (2008/264).
LPS was extracted from UPEC strains as previously described (11). Extracts were
analyzed on a 4 to 12% Bolt gel (Life Sciences) with silver staining (Thermo Scientiﬁc).
LPS was quantiﬁed by comparison to ﬁve standards (10, 5, 1, 0.5, and 0.1 mg/ml) of
commercially available E. coli LPS (Sigma). LPS-speciﬁc IgG2 titer was measured as
previously described with the following modiﬁcations (6). Patient sera were tested
against the cognate strain LPS unless otherwise indicated. HCS was pooled from at least
three healthy donors and used as a negative control in enzyme-linked immunosorbent
assays (ELISAs). The wells on the plates were coated with 1 g/ml of the appropriate
LPS. Patient sera were diluted across the plate (1:20 to 1:14,580). The secondary
antibody was monoclonal anti-human IgG2 (Fc speciﬁc) (diluted 1:2,000; Sigma-Aldrich)
followed by a tertiary antibody of alkaline phosphatase-labeled anti-mouse IgG (diluted
1:10,000). Absorbance readings were measured after 15-min incubation with the sub-
strate. Antibody titer was determined relative to pooled HCS. The sample cutoff was the
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average negative response plus 3 standard deviations. IgG was puriﬁed from serum
using a protein G column as previously described (6). Puriﬁed IgG was concentrated to
be equivalent to the initial serum.
Serum bactericidal assays (SBAs) were performed in triplicate as described previ-
ously (6). Serum or puriﬁed IgG was either undiluted or mixed 50:50 with either
phosphate-buffered saline (PBS) or HCS. Serum heated to 56°C for 20 min had no
bacterial killing activity and was used as a control. Statistical differences between
samples were determined by comparing log10 change in killing and area under the
curve via a Student’s t test. Analysis of the observed distribution of sequence types was
performed using a Wilson/Brown binomial test.
SUPPLEMENTAL MATERIAL
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.00920-18.
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